<DOC>
	<DOCNO>NCT01522872</DOCNO>
	<brief_summary>This phase 2 study design evaluate safety tolerability activity TH-302 dexamethasone without bortezomib pomalidomide subject relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Open-label Study TH-302 Dexamethasone With Without Bortezomib Pomalidomide Subjects With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>This initial study TH-302 subject relapsed/refractory multiple myeloma . It open-label dose-escalation study determine DLTs , MTD , safety preliminary efficacy TH-302 dexamethasone Simon two-stage expansion MTD . The study also investigate DLTs , MTD , safety preliminary efficacy TH-302 , dexamethasone bortezomib ; DLTs , MTD , safety preliminary efficacy TH-302 , dexamethasone pomalidomide . As , study separate four part . Treatment administer disease progression unacceptable toxicity , 12 cycle ( Arm A , Arm B Arm C ) 9 cycle ( Arm D ) complete .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Phosphoramide Mustards</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . At least 18 year age . 2 . Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee . 3 . Relapsed/refractory multiple myeloma standard therapy option anticipate result durable remission . 4 . Receipt least two prior therapy indicate protocol 5 . Subjects measurable disease 6 . ECOG performance status less equal 2 7 . Acceptable liver function 8 . Acceptable renal function 9 . Acceptable hematologic status 10 . For Part A , B , C subject : Women childbearing potential must negative serum pregnancy test woman men subject must agree use effective mean contraception partner indicate protocol For Part D subject : negative serum pregnancy test require within 10 14 day prior initiate pomalidomide , AND negative serum pregnancy test within 24 hour start pomalidomide must either commit continued abstinence heterosexual intercourse begin two acceptable method birth control least 28 day start take pomalidomide . Women childbearing potential must enroll follow requirement POMALYST REMS program , include adhere schedule pregnancy test . Men must agree use latex synthetic condom sexual contact woman child bear potential even vasectomy . All subject must counsel minimum every 28 day pregnancy precaution risk fetal exposure , female patient miss period abnormality menstrual bleeding . 11 . Subjects must adhere study visit schedule protocol requirement receive outpatient therapy laboratory monitor institute administers study drug . Exclusion Criteria Subjects meet follow exclusion criterion eligible enrol study : 1 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy skin change . ) 2 . Waldenstrom 's macroglobulinemia 3 . Localized radiation therapy measurable disease site ( ) within 2 week treatment 4 . New York Heart Association ( NYHA ) Class III IV , cardiac disease , myocardial infarction within 6 month prior Day 1 , unstable arrhythmia 5 . Significant neuropathy ( Grade 3 4 , Grade 2 pain ) time enrollment within 14 day enrollment 6 . Symptomatic brain metastasis ( unless previously treat well controlled period â‰¥ 3 month ) 7 . Severe chronic obstructive pulmonary disease hypoxemia opinion investigator physiological state lead hypoxemia 8 . Major surgery , diagnostic surgery , within 4 week prior Day 1 , without complete recovery 9 . Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy within 14 day prior first dose 10 . Previously treated malignancy , except adequately treat nonmelanoma skin cancer ( basal cell squamous cell ) , situ cancer , cancer subject diseasefree least 5 year 11 . Subjects participate investigational drug device study within 2 week prior study entry 12 . Known suspect active infection HIV , hepatitis A , hepatitis B , hepatitis C 13 . Subjects exhibit allergic reaction similar structural compound , biological agent , formulation similar TH302 , bortezomib ( subject enrol Part C ) , pomalidomide ( Part D ) , dexamethasone pimonidazole 14 . Females pregnant breastfeed 15 . Concomitant psychiatric disease medical condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study 16 . Unwillingness inability comply study protocol reason 17 . Previous cytotoxic therapy multiple myeloma within 3 week prior study entry ( 2 week biologic , novel therapy corticosteroid ) 18 . Subjects hormone replacement le 2 month ( subject hormone replacement least 2 month exclude provide HRT regimen remain unchanged conduct study ) . 19 . Prior peripheral stem cell transplant within 12 week start study 20 . Epilepsy convulsive disorder require active management 21 . Prior therapy pomalidomidecontaining regimen 22 . Subjects strong inducer strong inhibitor cytochrome P450 CYP3A4 CYP1A2 23 . Any medical condition opinion investigator would place patient increase risk toxicity pomalidomide treatment ( i.e . history recurrent serious thromboembolic event )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TH-302</keyword>
	<keyword>Relapsed/Refractory Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Phase 1/2</keyword>
	<keyword>Hypoxia</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Evofosfamide</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Pimonidazole</keyword>
</DOC>